Management of Drug Interactions

General Principles - Interaction Game Plan

• Goal: Minimize patient harm from drug-drug interactions (DDIs).

• Core Strategy: A systematic, proactive approach is crucial.

• Key Actions:

  • Avoid: If possible, use non-interacting alternatives.
  • Adjust: Modify dose, frequency, or timing.
  • Monitor: Closely observe for adverse drug reactions (ADRs) or therapeutic failure; consider therapeutic drug monitoring (TDM).
  • Discontinue: Stop one of the interacting drugs if risks outweigh benefits.

• Patient Education: Essential for adherence and early reporting of issues.

⭐ Most clinically significant interactions involve drugs with a narrow therapeutic index or those affecting critical pathways. 📌 Common enzyme inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) and inhibitors (e.g., Ketoconazole, Erythromycin, Ritonavir) are frequent culprits.

Proactive Management - Prevent & Predict

• Comprehensive Medication History:
  • Rx, OTC, herbals, supplements.
  • Allergies, past ADRs.
• Medication Reconciliation:
  • Essential at care transitions.
• Identify High-Risk:
  • Patients: Elderly, polypharmacy, organ dysfunction (renal/hepatic), NTI drug therapy.
  • Drugs: NTI (e.g., warfarin, digoxin, phenytoin), key enzyme inducers (e.g., rifampicin) & inhibitors (e.g., azoles).

  ⭐ Cytochrome P450 (CYP450) enzyme system metabolizes ~70-80% of clinical drugs; its inhibition/induction is a key cause of pharmacokinetic drug interactions.

• Utilize Decision Support:
  • CPOE with CDSS alerts.
  • Drug interaction databases.
  • Beers, STOPP/START criteria (elderly).
• Pharmacogenomic (PGx) Testing:
  • For specific gene-drug pairs (e.g., $CYP2C19$ & clopidogrel).
• Patient Education:
  • Stress adherence, reporting new issues. oka

Reactive Management - Detect & Correct

• Suspicion & Confirmation:
  • Detailed history (all drugs, diet, herbals).
  • Clinical exam for ADR/interaction signs.
  • Lab tests: drug levels, organ function (LFTs, RFTs).
• Causality Assessment:
  • Use Naranjo Algorithm or WHO-UMC criteria.
  • Assess temporal link: onset post-drug, dechallenge (improvement), rechallenge (recurrence).
• Identify Interacting Drugs:
  • Review all current medications (Rx, OTC, herbals).
  • Consult drug interaction databases (e.g., Micromedex, Lexicomp).
• Corrective Actions (Severity-dependent):
  • Stop drug if severe/life-threatening.
  • Reduce dose of one/both drugs; monitor.
  • Substitute with non-interacting alternative.
  • Monitor closely if drugs essential.
  • Stagger administration times if appropriate.
• Documentation & Reporting:
  • Document interaction & management in patient records.
  • Report significant ADRs/interactions to PvPI.

⭐ Naranjo Algorithm score >9 indicates a definite ADR; 5-8 probable; 1-4 possible; 0 doubtful.

Patient & System Factors - Holistic Handling

• Patient-Specific Considerations:
  • Age extremes (elderly, neonates): altered pharmacokinetics/dynamics.
  • Genetic factors (e.g., CYP450 polymorphisms): influences drug metabolism.
  • Comorbidities (renal/hepatic impairment): affects drug elimination.
  • Polypharmacy: significantly ↑ interaction risk; review regularly.
  • Patient education & adherence: key to prevention.
• System-Level Strategies:
  • Medication reconciliation: critical during care transitions.
  • Clinical Decision Support Systems (CDSS): utilize for interaction screening.
  • Multidisciplinary team approach: involve pharmacists.
  • Clear, unambiguous prescribing practices.
  • Robust ADR & interaction reporting systems.

⭐ Polypharmacy (concurrent use of ≥5 drugs) is a major predictor of adverse drug interactions, especially in geriatric patients.

High‑Yield Points - ⚡ Biggest Takeaways

• Dose adjustment is a key strategy to manage drug interactions.
• Monitor therapy closely, especially for drugs with narrow therapeutic windows.
• Substitute interacting drugs with safer alternatives when possible.
• Separate administration times to minimize pharmacokinetic interactions.
• Discontinue one drug if the interaction is unavoidable and severe.
• Be vigilant for CYP450 enzyme inducers/inhibitors and their impact.
• Educate patients about potential interaction symptoms for prompt reporting.